Wolfe: 'Roche Consumables Priced at $150/genome, Though There Are Some Nuances/Limits?; Launch Mid-2026'

Wolfe Research analyst Doug Schenkel reiterated an Outperform rating and $150.00 price target on Illumina (NASDAQ: ILMN).

The analyst comments "The $150/genome price is roughly in line with where we think ILMN pricing is based on this week's announcements, and can only be achieved with 20x reuse. Lower pricing can be achieved with simplex sequencing, but the quality is lower - best for counting applications. Importantly, it may be difficult to do duplex sequencing with targeted panels - if true this is a big deal and would be a limitation in some of the more important high growth market opportunities."

For an analyst ratings summary and ratings history on Illumina click here. For more ratings news on Illumina click here.

Shares of Illumina closed at $121.87 yesterday.

You May Also Be Interested In

• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• BTIG Starts Freenome Inc. (FRNM) at Buy
• Bang Mai Fang files for 5M share IPO at $5-$6/sh